SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws related to Sarepta Therapeutics following the death of a patient after treatment with its gene therapy, ELEVIDYS [1][2]. Group 1: Company Overview - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is facing scrutiny after a 16-year-old boy died from acute liver failure post-treatment with its gene therapy [1]. - The company's stock price experienced a significant decline of $27.81 per share, or 27.44$73.54 per share on March 18, 2025, following the news of the patient's death [2]. Group 2: Legal Investigation - Kessler Topaz Meltzer & Check, LLP is actively investigating the situation on behalf of Sarepta investors, focusing on potential securities law violations [1]. - The law firm has a history of prosecuting class actions related to securities fraud and has recovered billions for investors [3].